Publications by authors named "Palka Anand"

Claim this Profile
R
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Lindsay Fogel, Patrick C Roney, Jaeil Ahn, Adolfo Aleman, Fideliza Perez-Manon, Palka Anand

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.
Noa Biran, Eli Zolotov, David Vesole, Harsh Parmar, Pooja Phull, Palka Anand

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study.
Eli Zolotov, Maciej Kabat, Harsh Parmar, Palka Anand, Joshua Zenreich

Leuk Lymphoma· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic.
Catherine Lai, Arnold L Potosky, Colleen McGuire, Tania Lobo, Jaeil Ahn, Palka Anand

J Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Noa Biran, Elli Gourna Paleoudis, Rena Feinman, David H Vesole, Joshua Zenreich, Palka Anand

Am J Hematol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series.
David H Vesole, Joshua Richter, Noa Biran, Laura McBride, Palka Anand

Leuk Lymphoma· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Larysa Sanchez, David H Vesole, Joshua R Richter, Noa Biran, Elizabeth Bilotti, Palka Anand

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
David H Vesole, Elizabeth Bilotti, Joshua R Richter, Ann McNeill, Laura McBride, Palka Anand

Br J Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Paul G Richardson, David Siegel, Rachid Baz, Susan L Kelley, Nikhil C Munshi, Palka Anand

Blood· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Madiha Tufail, David S Siegel, Laura McBride, Elizabeth Bilotti, Erica Bello, Palka Anand

Clin Lymphoma Myeloma Leuk· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis